FDA Clears Drugs With Post-Market Safety Questions Faster Than It Re-labels
Executive Summary
FDA's "1early communication" program for alerting the public about potential drug safety issues produces a clean bill of health for products about 40 percent of the time, according to an analysis by "The Pink Sheet." And those positive decisions come much quicker than labeling changes the program has produced for drugs where genuine concerns have emerged
You may also be interested in...
FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.
Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New
FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.
Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New
FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.